| Modulation of doxorubicin sensitivity by a novel organic compound, oxalyl bis (N-phenyl) hydroxamic acid on acetyl aminofluorene-induced preneoplastic hepatocytes. | |
| | |
MedLine Citation:
|
PMID: 14643023 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Development of biochemical modulators and application of the same with anticancer drugs is a current approach of modern cancer chemotherapy. We report the effect of two novel hydroxamic acid derivatives, viz. oxaly bis (N-phenyl) hydroxamic acid (OBPHA) and succinyl bis (N-phenyl) hydroxamic acid (SBPHA) on doxorubicin sensitivity and on P-glycoprotein (P-gp) in acetyl amino fluorene (AAF) induced preneoplastic hepatocytes in vitro. OBPHA increases doxorubicin sensitivity in AAF induced preneoplastic hepatocytes compared to normal hepatocytes. SBPHA, with an additional -CH(2)-CH(2)- group than OBPHA does not modulate the sensitivity of doxorubicin. The mechanism of action of OBPHA and SBPHA and their in vivo toxicity on male Swiss mice has been studied. OBPHA in combination with doxorubicin (i.e. OBPHA+doxorubicin) has higher antitumour activity compared to doxorubicin alone group; in consequence, OBPHA may decrease the dose related side effect of doxorubicin. |
| | |
Authors:
|
S K Choudhuri; Surajit Majumder |
Related Documents
:
|
6470513 - Structure-activity relationships of retinoids in the morphogenesis of cutaneous appenda... 3045163 - Topical tretinoin in the treatment of aging skin. 21367203 - 220 relationship between follicular fluid metabolome and bovine oocyte developmental co... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cancer letters Volume: 202 ISSN: 0304-3835 ISO Abbreviation: Cancer Lett. Publication Date: 2003 Dec |
Date Detail:
|
Created Date: 2003-12-03 Completed Date: 2004-02-03 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7600053 Medline TA: Cancer Lett Country: Ireland |
Other Details:
|
Languages: eng Pagination: 25-34 Citation Subset: IM |
Affiliation:
|
Department of Environmental Carcinogenesis and Toxicology, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Calcutta 700026, India. soumitra01@vsnl.net |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
2-Acetylaminofluorene
/
toxicity* Animals Antibiotics, Antineoplastic / therapeutic use* Benzeneacetamides / therapeutic use* Calcium Channel Blockers / pharmacology Carcinogens / toxicity Cell Division / drug effects Dose-Response Relationship, Drug Doxorubicin / therapeutic use* Drug Synergism Drug Therapy, Combination Glutathione / metabolism Hepatocytes / drug effects*, metabolism, pathology Humans Hydroxamic Acids / therapeutic use* Male Mice Oxalates / therapeutic use* P-Glycoprotein / metabolism Precancerous Conditions / chemically induced, drug therapy*, metabolism Rats Rats, Sprague-Dawley Spleen / metabolism Survival Rate Tumor Cells, Cultured Verapamil / pharmacology |
| Chemical | |
Reg. No./Substance:
|
0/Antibiotics, Antineoplastic; 0/Benzeneacetamides; 0/Calcium Channel Blockers; 0/Carcinogens; 0/Hydroxamic Acids; 0/Oxalates; 0/P-Glycoprotein; 0/oxalyl bis(N-phenyl)hydroxamic acid; 23214-92-8/Doxorubicin; 52-53-9/Verapamil; 53-96-3/2-Acetylaminofluorene; 70-18-8/Glutathione |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Expression of CYP3A4 in human breast tumour and non-tumour tissues.
Next Document: Protoporphyrin IX-accumulation in human tumor cells following topical ALA- and h-ALA-application in ...